Pancreatic Cancer Research

ResearcherUniversity Medical Center Hamburg-EppendorfActive in the last 2 years

Gerrit Wolters‐Eisfeld

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2984-6515; OpenAlex author ID A5084919559. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
18
Papers, trials and grants by year

2014: 3 papers · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 9

  1. RARRES1 marks an immune-cold, chemoresistance-associated malignant epithelial subpopulation enriched in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00262-026-04361-8↗
  2. Development of a hypoxia-responsive macrophage prognostic model using single-cell and bulk RNA sequencing in pancreatic cancer. First author DOI 10.1371/journal.pone.0322618↗
  3. Unmasking metabolic dependencies in pancreatic cancer: aberrant polyamine synthesis as a promising new therapeutic target. Co-author DOI 10.1038/s41392-023-01662-7↗
  4. Truncated O-GalNAc glycans impact on fundamental signaling pathways in pancreatic cancer. Last author DOI 10.1093/glycob/cwab088↗
  5. Biperiden and mepazine effectively inhibit MALT1 activity and tumor growth in pancreatic cancer. Co-author DOI 10.1002/ijc.32567↗
  6. COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer. Last author DOI 10.1186/s12943-015-0386-1↗
  7. Pancreatic cancer. Co-author DOI 10.1111/bph.12401↗
  8. ABO blood group IgM isoagglutinins interact with tumor-associated O-glycan structures in pancreatic cancer. Last author DOI 10.1158/1078-0432.ccr-14-0716↗
  9. The multifunctional growth factor midkine promotes proliferation and migration in pancreatic cancer. Co-author DOI 10.1158/1541-7786.mcr-13-0467↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Cenap Güngör · 9 shared papers, 2014–2026 · strength 1.32
  2. Thilo Hackert · 3 shared papers, 2023–2026 · strength 0.95
  3. Heming Ge · 2 shared papers, 2025–2026 · strength 0.64
  4. Maximilian Bockhorn · 6 shared papers, 2014–2021 · strength 0.37
  5. Bianca T. Hofmann · 5 shared papers, 2014–2021 · strength 0.33
  6. Yuqiang Li · 1 shared paper, 2025 · strength 0.33
  7. Tarik Ghadban · 1 shared paper, 2026 · strength 0.32
  8. Jakob Robert Izbicki · 5 shared papers, 2014–2021 · strength 0.31
  9. Kai A. Bachmann · 2 shared papers, 2014–2021 · strength 0.16
  10. Faik Güntac Uzunoglu · 2 shared papers, 2014–2020 · strength 0.12
  11. Alexander T. El Gammal · 2 shared papers, 2015–2020 · strength 0.12
  12. Christoph Kahlert · 1 shared paper, 2021 · strength 0.12
  13. Leonie Konczalla · 1 shared paper, 2020 · strength 0.08
  14. Udo Schumacher · 1 shared paper, 2020 · strength 0.08
  15. Tamina Rawnaq · 1 shared paper, 2014 · strength 0.04
  16. Yogesh Kumar Vashist · 1 shared paper, 2014 · strength 0.04
  17. Florian Gebauer · 1 shared paper, 2014 · strength 0.04
  18. Michael Tachezy · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.